Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis ... (t-experienced patients with HCV genotype...)

HOME >> MEDICINE >> TECHNOLOGY

Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients

Date:4/23/2009

t-experienced patients with HCV genotype 1. In this study, low doses of ritonavir were used for metabolic inhibition to enhance the levels of SCH 900518 within the body and reduce the frequency of SCH 900518 dosing (BID vs. TID).

In the study, SCH 900518 administered as monotherapy exhibited potent antiviral activity, achieving 4.0-4.5 log10 decreases in viral load (HCV RNA) from baseline at day 8. SCH 900518 was well tolerated, with no drug related serious adverse events. Pharmacokinetic and pharmacodynamic modeling from this study was used to design the ongoing Phase IIa dose-finding study of SCH 900518 with ritonavir in combination with PEGINTRON and REBETOL. This study, known as NEXT-1, explores SCH 900518 in 200 mg, 400 mg or 600 mg once daily (QD) doses with low-dose ritonavir (100 mg) in combination with PEGINTRON and REBETOL (with and without a 4-week P/R lead-in period) in treatment-naive patients with HCV genotype 1.

About the HCV SPRINT-1 Study

In this Phase II study, known as HCV SPRINT-1 (HCV Serine Protease Inhibitor Therapy-1), boceprevir (800 mg TID) was evaluated in three treatment regimens: 4 weeks of PEGINTRON (1.5 mcg/kg once weekly) and REBETOL (800-1400 mg daily based on patient weight) therapy followed by the addition of boceprevir to the combination for 24 or 44 weeks (totaling 28 or 48 weeks of treatment), boceprevir in combination with PEGINTRON and REBETOL at the doses described above for 28 or 48 weeks, and, in Part II of the study, boceprevir in combination with PEGINTRON and low-dose REBETOL (400-1000 mg daily based on patient weight) for 48 weeks. In Part I of the study, the boceprevir regimens were compared to a control of PEGINTRON (1.5 mcg/kg once weekly) and REBETOL (800-1400 mg daily based on patient weight) alone for 48 weeks (an approved treatment regimen). In Part II of the study, boceprevir in combination with PEGINTRON and low-dose REBETOL for 48 weeks was compared t
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related medicine technology :

1. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
2. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
3. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
4. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
5. Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
6. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
7. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
8. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
9. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
10. The Anatomy of Clinical Trials: Greys Season Finale Leaves Public in the Dark About the Myths and Realities
11. Final Results of the CellCept(R) Spare the Nephron (STN) Study Show Maintenance Therapy is Associated with Improved Renal Function

Post Your Comments:

(Date:12/15/2009)... CITY, Dec. 15 Dynatronics ... signed a preferred vendor agreement to provide therapy ... Inc. (PTP), a nationwide network of physical, occupational ... be working with Preferred Therapy Providers," said Larry ... marketing at Dynatronics. "Their vast network of 1,100 ...

(Date:12/15/2009)... Dec. 15 ,, Reportlinker.com announces ... available in its catalogue: ,, Hepatitis ... Forecasts to 2015 ,, http://www.reportlinker.com/p0167309/Hepatitis-B-Vaccines---Pipeline-Analysis-and-Market-Forecasts-to-2015.html ... Analysis and Market Forecasts to 2015 ,, ... analysis specialist,s new report, "Hepatitis B Vaccines ...

(Date:12/15/2009)... NEW YORK, Dec. 15 Reportlinker.com ... is available in its catalogue: ,, ... http://www.reportlinker.com/p0168539/Boehringer-Ingelheim-GmbH-PharmaVitae-Profile.html ,, Introduction ... forecast performance for Boehringer Ingelheim in the ... strategy, portfolio and pipeline analysis and assessment ...

Breaking Medicine Technology:Dynatronics Inks Preferred Vendor Agreement with 1,100 Member Preferred Therapy Providers, Inc. 2 Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 2 Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 3 Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 4 Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 5 Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 6 Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 7 Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 2 Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 3 Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 4 Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 5 Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 6 Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 7 John Hancock Announces Enhancements to Group Long Term Care 28LTC 29 Insurance Products and Discount Program 49216 1 John Hancock Announces Enhancements to Group Long Term Care 28LTC 29 Insurance Products and Discount Program 49216 2 John Hancock Announces Enhancements to Group Long Term Care 28LTC 29 Insurance Products and Discount Program 49216 3 John Hancock Announces Enhancements to Group Long Term Care 28LTC 29 Insurance Products and Discount Program 49216 4 Accelerated Development of New Treatment for Multi Drug Resistant Tuberculosis 3A TB Alliance and Tibotec Announce Unique Partnership to Develop TMC20 49213 1 Accelerated Development of New Treatment for Multi Drug Resistant Tuberculosis 3A TB Alliance and Tibotec Announce Unique Partnership to Develop TMC20 49213 2 Accelerated Development of New Treatment for Multi Drug Resistant Tuberculosis 3A TB Alliance and Tibotec Announce Unique Partnership to Develop TMC20 49213 3 New Study Finds 1 in 4 Multiple Sclerosis Patients With High Out of Pocket Costs Not Filling Prescriptions 49210 1 New Study Finds 1 in 4 Multiple Sclerosis Patients With High Out of Pocket Costs Not Filling Prescriptions 49210 2

[0] Dynatronics Inks Preferred Vendor Agreement with 1,100 Member Preferred Therapy Providers, Inc.[0] Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 [0] Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile

... fMRI Study Completed and Reported Today ... Higher Repeat Dose Study Completed, HAMBURG, Germany and ... EVT) is pleased to announce the,preliminary findings of a ... subtype selective NMDA receptor antagonist, EVT,101. The study was ...

... Study Highlights Growing Therapeutic Value of Cord Blood ... Stems cells derived,from umbilical cord blood are showing ... from a new preclinical study,published in the March ... by researchers from the University of South Florida ...

Other Medicine Technology:Evotec's EVT 101 Shown to Penetrate the Brain in Man and to Modulate Brain Activity During the Performance of Cognitive Tasks 2 Evotec's EVT 101 Shown to Penetrate the Brain in Man and to Modulate Brain Activity During the Performance of Cognitive Tasks 3 Early Research Suggests Umbilical Cord Blood Cell Therapy May Reduce Progression of Alzheimer's Disease 2 Early Research Suggests Umbilical Cord Blood Cell Therapy May Reduce Progression of Alzheimer's Disease 3 Early Research Suggests Umbilical Cord Blood Cell Therapy May Reduce Progression of Alzheimer's Disease 4 Early Research Suggests Umbilical Cord Blood Cell Therapy May Reduce Progression of Alzheimer's Disease 5

Evotec's EVT 101 Shown to Penetrate the Brain in Man and to Modulate Brain Activity During the Performance of Cognitive Tasks Early Research Suggests Umbilical Cord Blood Cell Therapy May Reduce Progression of Alzheimer's Disease

(Date:12/15/2009)... Accelify is proud to announce the addition ... David will serve as Director of Development in the ... Board of Advisors. ,, David Tokofsky was ... of Education in June 1995. As the Board Member ... 600,000 stretching from Northeast Los Angeles through East Los ...

(Date:12/15/2009)... Reportlinker.com announces that a ... in its catalogue: ,, The ... Market Forecasts to 2015, Competitive Benchmarking, ... ,, http://www.reportlinker.com/p0168098/The-Future-of-Cardiovascular-Diseases-Therapeutics---Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis.html ,, ... released its latest research "The Future ...

(Date:12/15/2009)... Dec. 15 Hospira, Inc. (NYSE: ... in generic injectable pharmaceuticals, and Orchid Chemicals ... a leading Indian pharmaceuticals company and among ... today announced an agreement for Hospira to ... business for approximately $400 million. ,, ...

(Date:12/15/2009)... Visits to a gynaecologist or midwife are generally ... but could offer so much more. Women, doctors ... great opportunities for dialogue about sexual health, reveals ... University of Gothenburg, Sweden. , Many young women ... Almost 500 women aged 23-29 answered questions about ...

(Date:12/15/2009)... seen as a potential heart disease therapy, raising high-density ... transfer protein may not be effective, a new study ... Research Center on Aging (USDA HNRCA) at Tufts University ... association between low plasma cholesterol ester transfer protein (CETP) ... Framingham Heart Study population. , CETP is a protein ...

[0] Accelify Announces the Addition of David Tokofsky to its National Board of Advisors [0] Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis [0] Hospira to Acquire Orchid's Generic Injectable Pharmaceuticals Business [0] More about sex and relationships needed at gynecological visits [0] Low cholesterol transfer protein activity associated with heart disease risk

... ... Offering, LAKEWOOD, N.J., ... a national gastrointestinal (GI),offering to further expand its diagnostic services. The ... a regional laboratory into a national anatomic pathology leader,offering a range ...

... 19 Align Technology,Inc. (Nasdaq: ALGN ), today ... president of research and development, effective June 16. Mr. ... Officer, Thomas,M. Prescott and lead the Company,s research and ... and we are pleased to,have Dana on board to ...

... Minneapolis-St. Paul, DC and San,Francisco as Most Heart Friendly ... the No. 1,killer of women, may hit closer to ... Red For Women movement released a study,conducted by Sperling,s ... heart friendly cities for women. Minneapolis-St. Paul took the,title ...

... May 19 Chiltern, a leading global research,organization, announced ... of,General Manager, Latin America., The Latin American operation ... Podesta and will be primarily focused on supporting our,Global ... 9,years experience in clinical research, where he has held ...

... happen to men, not only to women, according to Group ... Domestic violence in men is under-studied and often hiddenmuch as ... Robert J. Reid, MD, PhD, an associate investigator at the ... to know theyre not alone. His findings confirm some common ...

... ... Defy Economic Downturn and Remind Policy Makers that AIDS is Still ... a Crisis at Home., NEW YORK, May ... and most successful AIDS Walk,ever held, setting a fundraising record even in the face of ...

Other Medicine News:Health News:Lakewood Pathology Launches National Gastroinestinal Diagnostic Services 2 Health News:Align Technology Names Dana C. Cambra as VP, Research & Development 2 Health News:American Heart Association Ranks America's Most Heart Friendly Cities for Women 2 Health News:American Heart Association Ranks America's Most Heart Friendly Cities for Women 3 Health News:American Heart Association Ranks America's Most Heart Friendly Cities for Women 4 Health News:American Heart Association Ranks America's Most Heart Friendly Cities for Women 5 Health News:Chiltern Expands Its Global Reach to Latin America 2 Health News:Men experience domestic violence, with health impact 2 Health News:AIDS Walk New York Raises $7.05 Million 2

Lakewood Pathology Launches National Gastroinestinal Diagnostic Services Align Technology Names Dana C. Cambra as VP, Research & Development American Heart Association Ranks America's Most Heart Friendly Cities for Women Chiltern Expands Its Global Reach to Latin America Men experience domestic violence, with health impact AIDS Walk New York Raises $7.05 Million

... presents the i.Series refrigerator ... solutions for the blood ... features than ever before, ... are at the forefront ...

... the i.Series refrigerator iB120, ... for the blood bank. ... than ever before, i.Series ... at the forefront of ...

... precise requirements of blood banking and ... Equipment meets American Association of Blood ... (ANRC) and U.S. Food & Drug ... and platelet incubators feature alarm systems ...

The TBR-360-1-GD is a large capacity upright style operating temperature +4C. It is specially designed refrigerators for the storage of blood in standard 500ml bags, complying with Australian Standar...

Medicine Products:

i.Series iB256 Blood Bank Refrigerator i.Series iB120 Blood Bank Refrigerator Blood Bank Refrigerator 3866/3868 Blood Storage Refrigerator TBR-360-1-GD

Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis ...(t-experienced patients with HCV genotype...),Health